AptarGroup (ATR) is trading lower on Friday, May 1, 2026, as investors react to first-quarter 2026 results that showed softer profitability even as reported revenue rose. The company reported adjusted EPS of $1.19, down from $1.30 a year earlier at comparable exchange rates, and adjusted EBITDA margin of 19.2% versus 20.7% in the prior-year quarter, signaling margin pressure across the portfolio.

For the quarter ended March 31, 2026, Aptar reported net sales up 11% year over year to $982.9 million, while core sales were flat. Reported net income decreased 8% to about $73 million and diluted EPS slipped to $1.12 from $1.17; management attributed pressure in Pharma to reduced emergency-medicine category sales (destocking) and also flagged operational headwinds, including maintenance issues and temporary plant closures tied to extreme weather that weighed on Closures profitability.

Aptar guided for Q2 2026 adjusted EPS of $1.32 to $1.40 (assuming a 22.5%–24.5% effective tax rate and 1.18 EUR/USD), positioning the next quarter as a rebound period excluding ongoing destocking effects in emergency medicine. The company also announced a planned leadership transition, naming Gael Touya as next CEO effective September 1, 2026.

Investors will likely focus on whether emergency-medicine destocking normalizes quickly enough to restore Pharma growth, and whether operational issues and weather-related interruptions have fully cleared to support margin recovery. Follow-through on Q2 guidance and updates on mix, plant reliability, and demand in injectables tied to GLP-1 and biologics will be key to sentiment from here.